No Data
No Data
Zhejiang Shapuaisi Pharmaceutical (603168.SH): obtained the 'Pharmaceutical Registration Certificate' for Diquafosol Sodium Eye Drops.
On September 3, Guilonghui announced that Zhejiang Shapuaisi Pharmaceutical (603168.SH) has received the Drug Registration Certificate issued by the National Medical Products Administration. The approved diquafosol sodium eye drops are single-dose eye drops without preservatives, suitable for dry eye patients diagnosed with corneal epithelial damage associated with tear abnormalities.
Sharp Ace 2024 Semi-Annual Report
Sharp Ace 2024 Semi-Annual Report Summary
Decline in revenue from the sales sector, zhejiang shapuaisi pharmaceutical incurs losses in H1 | interpretations
①Affected by factors such as the decline in sales of eye drops and cephalosporin drugs, the H1 performance of Zhejiang Shapuaisi pharmaceutical has declined significantly, resulting in a year-on-year loss. ②The company's main business, the commodity sales sector, saw a year-on-year decrease in revenue of more than 40%.
Zhejiang Shapuaisi Pharmaceutical (603168.SH): a net loss of 247.169 million yuan in the first half of the year.
Zhejiang Shapuaisi Pharmaceutical (603168.SH) released its semi-annual report for 2024, achieving revenue of 0.237 billion yuan in the first half of the year, a year-on-year decrease of 30.65%; net income attributable to shareholders of the listed company was -24.7169 million yuan.
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd.'s (SHSE:603168) Market Cap Dropped CN¥372m Last Week; Individual Investors Bore the Brunt
No Data